US STOCKS-Futures rise as focus shifts to inflation data, Fed meet

Since last week, the rally has broadened beyond megacaps to include more economically sensitive sectors such as energy, industrial and small-cap stocks as data continues to show a resilient U.S. economy despite higher interest rates. Goldman Sachs on Friday raised its year-end price target for the benchmark S&P 500 to 4,500 from 4,000, citing the broadening of the market rally.

U.S. stock index futures rose on Monday, setting Wall Street up for a fresh round of gains, while investors awaited inflation data and the Federal Reserve's interest rate decision this week. The U.S. Labor Department's consumer price index reading on Tuesday, also the first day of the Fed's meeting, is expected to show inflation cooled slightly in May but core prices are likely to have remained elevated.

Traders see a 72% chance of the central bank hold interest rates at the 5%-5.25% range on Wednesday, while pricing in a 56% chance of a 25-basis-point increase in July, according to the CME Fedwatch tool. The benchmark S&P 500 notched gains for a fourth straight week on Friday, building on a 20% rise from its October 2022 lows, heralding the start of a new bull market as defined by some market participants.

A rally in megacap stocks, better-than-expected quarterly earnings and hopes that the Fed might be nearing the end of its tightening cycle have caused indexes to rise in recent weeks. Since last week, the rally has broadened beyond megacaps to include more economically sensitive sectors such as energy, industrial and small-cap stocks as data continues to show a resilient U.S. economy despite higher interest rates.

Goldman Sachs on Friday raised its year-end price target for the benchmark S&P 500 to 4,500 from 4,000, citing the broadening of the market rally. At 7:36 a.m. ET, Dow e-minis were up 36 points, or 0.11%, S&P 500 e-minis were up 11.5 points, or 0.27%, and Nasdaq 100 e-minis were up 69.5 points, or 0.48%.

The CBOE volatility index edged up after hitting pre-pandemic levels in the previous week, up 0.71 point to 14.5. Biogen shares rose 2.5% in premarket trading after a U.S. FDA panel of advisers unanimously backed its Alzheimer's drug, Leqembi, stoking hopes that a traditional approval for the treatment might not come with major new safety warnings.

Adobe shares gained 1.9% after Jefferies raised the Photoshop maker's price target to $530, the second highest on Wall Street. Oracle rose 4.1% as J.P. Morgan hiked its price target to $109, ahead of the cloud and enterprise software firm's fourth-quarter results later in the day.

U.S.-listed shares of Nio added 4.3% after the Chinese EV maker slashed prices on its cars as lukewarm sales pressure the company. Nasdaq Inc slid 7.5% after the exchange operator said it would buy Thoma Bravo-owned software firm Adenza for $10.5 billion.